Zhang ZH, Guo JT, Xie Y, Sun SY. Essential role of postoperative follow-up in the management of clear cell sarcoma. World J Clin Cases 2024; 12(23): 5299-5303 [PMID: 39156081 DOI: 10.12998/wjcc.v12.i23.5299]
Corresponding Author of This Article
Si-Yu Sun, MD, PhD, Chief Doctor, Director, Professor, Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, Liaoning Province, China. sun-siyu@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 16, 2024; 12(23): 5299-5303 Published online Aug 16, 2024. doi: 10.12998/wjcc.v12.i23.5299
Essential role of postoperative follow-up in the management of clear cell sarcoma
Zi-Han Zhang, Jin-Tao Guo, Ying Xie, Si-Yu Sun
Zi-Han Zhang, Jin-Tao Guo, Ying Xie, Si-Yu Sun, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Jin-Tao Guo, Si-Yu Sun, Engineering Research Center of Ministry of Education for Minimally Invasive Gastrointestinal Endoscopic Techniques, Shenyang 110004, Liaoning Province, China
Author contributions: Zhang ZH, Guo JT, Xie Y, Sun SY contributed to this paper; Zhang ZH designed the outline of the manuscript and drafted the article; Guo JT was responsible for the revision of the manuscript; Xie Y contributed to the editing the manuscript; Sun SY was the study supervisor and was responsible for the revision of the manuscript.
Supported byLiaoning Province Applied Basic Research Program Joint Program Project, No. 2022JH2/101500076; Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program, No. RC200438; Tree Planting Program of Shengjing Hospital, No. M1595; and the Doctoral Start-up Foundation of Liaoning Province, No. 2022-BS-127.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Si-Yu Sun, MD, PhD, Chief Doctor, Director, Professor, Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, Liaoning Province, China. sun-siyu@163.com
Received: April 7, 2024 Revised: May 18, 2024 Accepted: June 4, 2024 Published online: August 16, 2024 Processing time: 89 Days and 2.8 Hours
Abstract
Clear cell sarcoma (CCS) is a rare melanocytic soft tissue sarcoma known for its propensity to metastasize to the lymph nodes and typically has an unfavorable prognosis. Currently, surgical resection is the primary treatment for localized CCS, while radiotherapy and chemotherapy are preferred for metastatic cases. The roles of adjuvant chemotherapy, radiotherapy, and lymph node dissection are controversial. Although immunotherapy has emerged as a promising avenue in CCS treatment research, there are no established clinical standards for postoperative follow-up. This editorial discusses a recent article by Liu et al, with a focus on current diagnostic modalities, treatment approaches, and the challenging prognosis associated with CCS. Our aim is to underscore the importance of long-term patient follow-up in CCS management.
Core Tip: Clear cell sarcoma (CCS) is a rare subtype of melanocytic soft tissue sarcoma distinguished by its propensity for metastasis and recurrence. Survival rates markedly diminish in patients with advanced CCS compared with those with early-stage disease. The insidious nature of early occult onset and the limited responsiveness of CCS to chemoradiotherapy underscore the critical importance of routine postoperative follow-up for early detection of recurrent cases, which is crucial for enhancing patient prognosis.
